Cart
sales@molnova.com
FDL169
CAS No. 1628416-28-3
FDL169( CFTR corrector 2? )
Catalog No. M20072 CAS No. 1628416-28-3
FDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 80 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 237 | In Stock |
|
| 50MG | 357 | In Stock |
|
| 100MG | 530 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFDL169
-
NoteResearch use only, not for human use.
-
Brief DescriptionFDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.
-
DescriptionFDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.
-
In Vitro——
-
In Vivo——
-
SynonymsCFTR corrector 2?
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research AreaMetabolic Disease
-
IndicationCystic fibrosis
Chemical Information
-
CAS Number1628416-28-3
-
Formula Weight486.49
-
Molecular FormulaC27H23FN4O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 30 mg/mL (61.7 mM);Water: Insoluble
-
SMILESCCOc1ccc2c(nn(CC(=O)N(C)c3ccc4nc(C)oc4c3)c(=O)c2c1)-c1cccc(F)c1
-
Chemical Name2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1h)-yl)-n-methyl-n-(2-methylbenzo[d]oxazol-6-yl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gross N. The COPD Pipeline XXXII. Chronic Obstr Pulm Dis. 2016 Jul 14;3(3):688-692.
molnova catalog
related products
-
Icenticaftor
Icenticaftor is an orally active potentiator of?CFTR channel.
-
OSSK-674842
A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.
-
GLPG-1837
GLPG-1837 (ABBV-974)?is a potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively.
